‍

‍What Is HRT?

‍

Hormone replacement therapy (also called menopausal hormone therapy) supplies oestrogen, with or without a progestogen, to restore more physiological levels after ovarian hormone production declines. Routes include oral tablets, transdermal patches or gels, vaginal preparations, and in some practices compounded bioidentical formulations. [1] [2]

• Oestrogen primarily relieves vasomotor symptoms (hot flushes, night sweats), supports genitourinary tissue, and influences bone, brain and vascular signalling.
• Progestogen (progesterone or a synthetic progestin) is added for women with an intact uterus to protect the endometrium.
• Bioidentical HRT typically refers to hormones chemically identical to those produced by the human body (for example 17β-oestradiol, micronised progesterone). These may be licensed products or, in selected cases, compounded preparations tailored by dose and route. [3] [4]

From a functional-medicine matrix view, HRT is one lever within a broader plan that also optimises sleep and relaxation, nutrition (protein, fibre, phytonutrients, adequate calories), exercise and movement, stress physiology, relationships and social connection, and removal of mediators such as excess alcohol, ultra-processed food or untreated sleep apnoea.

‍

‍

Key Benefits of HRT (with Clinical Context)

‍

When started in appropriately selected women—especially nearer to menopause onset—HRT can produce meaningful improvements:

• Vasomotor and sleep symptoms: Oestrogen remains the most effective therapy for hot flushes and night sweats, often improving sleep continuity and daytime function. [1] [5]
• Genitourinary syndrome of menopause: Local or systemic oestrogen can reduce vaginal dryness, discomfort with intercourse and urinary urgency related to tissue atrophy. [6] [1]
• Bone health: Oestrogen helps maintain bone mineral density and reduces fracture risk by slowing osteoclast activity and supporting skeletal structural integrity. [1] [7]
• Quality of life, mood and cognition (selected patients): Many women report better mood stability, reduced brain fog and improved vitality. Benefits are most consistent for those with bothersome symptoms; HRT is not a first-line treatment for clinical depression or dementia prevention. [8] [9]
• Metabolic and body-composition support (adjunctive): In the context of resistance training, adequate protein and metabolic health optimisation, stabilised hormones can make body-composition goals more achievable for some patients.

Evidence strength note: Symptom relief for vasomotor complaints has strong consensus in menopausal-medicine practice. [1] Cardiometabolic and cognitive outcomes are timing- and patient-dependent; benefits are more favourable when therapy begins before age 60 or within roughly 10 years of menopause onset in women without contraindications (the “timing hypothesis”). [10] [8] Longer-term disease-prevention claims require individualised risk–benefit discussion rather than blanket recommendation. HRT is not recommended solely for primary prevention of cardiovascular disease. [11] [12]

‍

Interconnections matter: poor sleep amplifies cortisol and insulin dysregulation; chronic stress can worsen vasomotor symptoms; gut and liver biotransformation influence hormone metabolites; and low muscle mass or sedentary behaviour compounds bone and metabolic risk. HRT works best when these domains are addressed in parallel.

‍

‍

Potential Risks and Considerations — Is HRT Safe?

‍

Is HRT safe? For many healthy women who start therapy near menopause, modern regimens have an acceptable safety profile when individualised. Safety is not universal; it depends on age, time since menopause, dose, route, personal and family history, and ongoing monitoring. [1] [2] [13]

Key considerations include:

• Breast cancer: Combination oestrogen-plus-progestogen therapy has been associated with a small increase in breast cancer risk with longer-term use in some large datasets; oestrogen-alone (after hysterectomy) has shown different patterns. Absolute risks for most newly menopausal women remain low and should be framed in absolute, not only relative, terms. [1] [8]
• Cardiovascular and thrombotic risk: Oral oestrogen undergoes first-pass hepatic metabolism and can increase clotting-factor production. Transdermal oestradiol generally carries a lower venous thromboembolism risk signal and is often preferred in women with higher baseline clot or stroke risk factors. [14] [15] Starting HRT well after age 60 or more than a decade past menopause shifts the risk–benefit balance less favourably for systemic therapy in many guidelines. [1]
• Stroke and gallbladder disease: Small absolute increases have been observed with certain oral regimens.
• Endometrial protection: Unopposed systemic oestrogen in women with a uterus raises endometrial hyperplasia and cancer risk; adequate progestogen is required. [1]
• Other: Individual factors—migraine with aura, uncontrolled hypertension, active liver disease, history of hormone-sensitive cancer, or undiagnosed vaginal bleeding—require specialist evaluation before any hormone use.

Practical safety principles:

• Prefer the lowest effective dose for the duration needed to meet goals.
• Favour transdermal oestradiol plus micronised progesterone when systemic therapy is chosen and the uterus is present, unless specific indications dictate otherwise. [14] [4]
• Reassess regularly (symptoms, blood pressure, breast imaging per guidelines, and targeted labs as clinically indicated). Arbitrary limits should not be placed on duration; decisions should be individualised with shared decision-making. [2] [13]
• Combine with lifestyle: Mediterranean-style or anti-inflammatory nutrition, strength training, zone-2 movement, sleep optimisation and stress-reduction practices lower overall cardiometabolic and inflammatory burden.

‍

‍

Who Is HRT For?

‍

Good candidates often include women who:

• Have moderate-to-severe vasomotor or genitourinary symptoms that impair quality of life.
• Are under 60 or within about 10 years of the final menstrual period.
• Have no major contraindications (for example prior hormone-sensitive breast cancer, active thromboembolic disease, unexplained bleeding, severe active liver disease).
• Prefer a root-cause, monitored approach that also addresses lifestyle and nutrient status. [1] [5]

‍

Longevity-focused considerations are particularly relevant for women seeking to optimise healthspan. In appropriately selected individuals, HRT may support:

• Bone protection: Reduced fracture risk and maintenance of bone mineral density, helping preserve mobility and independence into later decades. [1] [7]
• Cardiovascular risk reduction: Potential benefits for lipid profiles, vascular function and overall cardiometabolic health when initiated near menopause (timing hypothesis), especially alongside lifestyle optimisation. [10] [8] [11]
• Cognitive health: Possible support for mood stability, reduced brain fog and maintenance of cognitive function in symptomatic women, with emerging interest in neuroprotective effects when started early. [8] [9]

‍

HRT is generally not first-line solely for chronic disease prevention in asymptomatic women. [11] Women with premature ovarian insufficiency or early menopause often warrant hormone therapy at least until the average age of natural menopause for bone, cardiovascular and quality-of-life protection unless contraindicated. [12] [16]

A functional work-up may explore antecedents (genetics, surgical menopause, chemotherapy), triggers (abrupt hormone withdrawal, major stress, illness), and mediators (insulin resistance, chronic inflammation, gut dysbiosis, nutrient cofactor insufficiency, circadian disruption). Labs might include oestradiol, progesterone, FSH (contextually), thyroid panel, fasting insulin/glucose or HOMA-IR, lipid particle context, hs-CRP, vitamin D and others personalised to the matrix—not a rigid panel.

‍

‍

Modern Options: Bioidentical HRT and Personalised Regimens

‍

Bioidentical HRT uses molecules identical to endogenous hormones. Licensed examples include 17β-oestradiol (patches, gels, sprays, some oral) and micronised progesterone. Compounded bioidentical hormones are used in some practices for customised doses or combinations not available commercially; quality, consistency and monitoring become especially important, and shared decision-making should include discussion of regulatory and evidence differences versus approved products. [3] [17]

Modern best practices emphasise:

• Route matters: Transdermal oestradiol avoids first-pass effects and is often preferred for safety signals related to clotting. [14] [15]
• Progesterone choice: Micronised progesterone is frequently selected for endometrial protection and tolerability, with some evidence trending towards a favourable profile versus certain synthetic progestins. [4]
• Local therapy: Low-dose vaginal oestrogen for genitourinary symptoms has minimal systemic absorption and a favourable safety profile for many women, including some who cannot use systemic HRT. Vaginal DHEA and oral ospemifene are additional options in selected cases. [6] [9]
• Off-licence use of testosterone for symptom relief: In selected women, off-licence testosterone therapy (typically as a cream or gel) is used to address persistent symptoms such as low libido, reduced energy, brain fog and mood changes that have not fully responded to oestrogen and progesterone alone. This approach is employed in clinical practice for carefully evaluated patients with documented low testosterone levels and ongoing symptoms, with regular monitoring of levels, haematocrit and clinical response. [9]
• Non-hormonal adjuncts: SSRIs/SNRIs, gabapentin, fezolinetant (neurokinin-3 receptor antagonist), cognitive-behavioural strategies, paced respiration, weight-bearing exercise and cooling techniques remain valuable, especially when hormones are contraindicated or declined. [5]

Implementation is stepwise: clarify goals → review history and examination → baseline assessment → shared choice of preparation and dose → short-interval follow-up for symptom response and tolerance → titrate → long-term surveillance. Nutrition (phytoestrogen-containing foods as complementary, not equivalent), strength training, protein adequacy, alcohol moderation and sleep hygiene amplify results and support detoxification and metabolic pathways.

‍

‍

Conclusion

‍

Hormone replacement therapy can be a powerful, evidence-aligned tool for relieving menopausal symptoms, protecting bone and restoring quality of life when matched to the right person, dose, route and timing. HRT benefits are clearest for bothersome vasomotor and genitourinary symptoms; is HRT safe depends on individual risk profile and regimen design; bioidentical HRT and modern transdermal options offer refined choices; and the best menopause treatment plans integrate hormones with lifestyle, nutrition and root-cause evaluation across the functional-medicine matrix. [1] [2] [13]

If you are navigating perimenopause or menopause and want a personalised, systems-based assessment, schedule a consultation. Bring your symptom timeline, prior labs, family history and goals. Together we can determine whether HRT, non-hormonal strategies, or a combined plan is the safest and most effective path for you.

‍

‍

References

1. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022. doi:10.1097/GME.0000000000002028 [1]
2. Hamoda H, Panay N, Pedder H, et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health. 2020. doi:10.1177/2053369120957514 [2]
3. Hamoda H, Mukherjee A, Morris E, et al. Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause. Post Reproductive Health. 2022. doi:10.1177/20533691221104879 [13]
4. The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. doi:10.1097/gme.0000000000001609 [6]
5. Goldštajn MS, Mikuš M, Ferrari F, et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Archives of Gynecology and Obstetrics. 2022. doi:10.1007/s00404-022-06647-5 [14]
6. Mehta JM, Kling JM, Manson JE. Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts. Frontiers in Endocrinology. 2021. doi:10.3389/fendo.2021.564781 [8]

‍